Details

Autor(en) / Beteiligte

• Hughes, A R
• Spreen, W R
• Mosteller, M
• Warren, L L
• Lai, E H
• Brothers, C H
• Cox, C
• Nelsen, A J
• Hughes, S
• Thorborn, D E
• Stancil, B
• Hetherington, S V
• Burns, D K
• Roses, A D

Titel

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility

Ist Teil von

• The pharmacogenomics journal, 2008-12, Vol.8 (6), p.365-374

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2008

Quelle

MEDLINE

Beschreibungen/Notizen

• The hypersensitivity (HSR) to abacavir (ABC) pharmacogenetics (PGx) program represents the progression from an exploratory discovery to a validated biomarker. Within the program, two retrospective PGx studies were conducted to identify HIV-1 patients at increased risk for ABC HSR, a treatment-limiting and potentially life-threatening adverse event. A strong statistical association between the major histocompatibility complex allele, HLA-B*5701 , and clinically diagnosed ABC HSR was identified but varied between racial populations. Subsequently, ABC skin patch testing was introduced as a research tool to supplement clinical case ascertainment. In a randomized, prospective study evaluating the clinical utility of HLA-B*5701 screening, avoidance of ABC in HLA-B*5701 -positive patients significantly reduced clinically diagnosed ABC HSR and eliminated patch test-positive ABC HSR. Finally, a retrospective PGx study supports the generalizability of the association across races. Prospective HLA-B*5701 screening should greatly reduce the incidence of ABC HSR by identifying patients at high risk for ABC HSR before they are treated.